Hepion Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Apr 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 16, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
Date: April 16, 2024
| HEPION PHARMACEUTICALS, INC. | |
| By: | /s/ JOHN CAVAN |
| John Cavan | |
| Interim Chief Executive Officer/Chief Financial Officer(Interim Principal Executive Officer and Financial Officer) |
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints, John Cavan, and each of them acting individually, as his attorney-in-fact, with full power of substitution and resubstitution, for him in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ JOHN CAVAN | Interim Chief Executive Officer/Chief Financial Officer | April 16, 2024 |
| John Cavan | (Interim Principal Executive Officer and Financial Officer) | |
| /s/ JOHN BRANCACCIO | Chairman, Board of Directors | April 16, 2024 |
| John Brancaccio | ||
| /s/ TIMOTHY BLOCK | Director | April 16, 2024 |
| Timothy Block | ||
| /s/KAOUTHAR LBIATI | Director | April 16, 2024 |
| Kaouthar Lbiati | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.